Keros Therapeutics rises after adoption of poison pill, review of strategic options

Keros Therapeutics

10/04/2025 16:51

Updates

** Shares of drug developer Keros Therapeutics KROS.O rise as much as 18.8% to an over one-month high of $12.27

     ** Stock set for its best day in over a year, if gains hold

** KROS says it has adopted a poison pill defense to fend off hostile takeovers, after some investors indicated a desire to influence the control of the drug developer

** Company says the poison pill, known as a limited-duration stockholder rights plan, was intended to protect the integrity of a strategic review process, which includes a possible sale of the company

 ** KROS says it would consider a range of strategic alternatives

 ** Company did not disclose the identity of the shareholders

** Up to last close, shares have fallen 34.7% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))